MedImmune chronicles

Since late 2000, MedImmune's stock performance has lagged its peers, as gauged by a price-weighted index consisting of Amgen (AMGN), Biogen Idec (BIIB), Genentech (DNA), Genzyme (GENZ) and Gilead (GILD). In fact, prior to last week's acquisition announcement, MEDI was off 13% from the start of 2000, while an index of its peers was up 116%. Below are selected MEDI events tracked against the company's weekly stock price. The initial values are indexed to 100 as of Dec. 31, 1999. A. 10/2/00 - MEDI falls $20.50 (27%) to $56.75 after an analyst lowered his rating to "market performer" from "buy" and lowered his non-U.S. sales estimate for Synagis palivizumab to prevent pediatric RSV infection for the 2000-01 and 2001-02 seasonsB. 1/15/02 - Completes acquisition of Aviron for $1.5B, from which MEDI acquired its FluMist intranasal influenza vaccineC. 12/17/02 - FDA's Vaccines and Related Biological Products Advisory Committee recommends approval of FluMist

D. 6/9/03 - Obtains North American rights to Micromet's MT103 bispecific T cell engager (BiTE) to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The companies also agreed to develop up to six new products based on the BiTE platform.E. 6/17/03 - FDA approves FluMist F. 7/10/03 - Raises $500M in a private placement...